Catalyst Calendar
Scope

Mon, Jun 29, 2026

1 updates
ZURA
7:30 AM

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline data expected Q4 2026 TibuSURE has exceeded the 80 participant enrollment

Enrollment • Phase 2Enrollment milestone Mon, Jun 29, 2026zurabio.com

Thu, May 14, 2026

1 updates
ZURA
7:30 AM

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev. --(BUSINESS WIRE)--May 14, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory

zurabio.com

Wed, May 13, 2026

1 updates

Thu, May 7, 2026

1 updates

Mon, May 4, 2026

1 updates
ZURA
4:05 PM

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev. --(BUSINESS WIRE)--May 4, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory

zurabio.com